Recent Comments
- Charles Carroll on Daily Alcohol is Not OK
- Charles Carroll on A food-borne illness mystery and what is wrong with current medical schools
- Is Italian flour healthier than American? | Quality of Life Clinic on Celiac disease is not reduced by breast feeding or delaying the introduction of gluten
- LB on The final House report on COVID
- Joy Smith on The Declaration of Pandemics
Most Viewed Posts
- Exclusive: Why the COVID “mRNA” vaccines are actually DNA gene therapies that must be removed from the market (31,402)
- Pfizer admits in federal court that the COVID gene therapies were never approved through the FDA (20,827)
- The Healthcare Channel hits 10 (18,452)
- New treatment paradigm for C. Diff colitis (17,737)
- How the FDA regulates compounding pharmacies (16,946)
- I discuss the handling of the COVID-19 outbreak on The Joe Piscopo radio show (16,898)
- Gordon Guyatt, MD: Update on the problem of clinical trials being stopped early to inflate efficacy of drugs (16,671)
- The Who’s Teen Cancer Lounge at Sloan Kettering opens (14,161)
- The new CDC guidelines for prescribing opioid pain pills (12,880)
- Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital. (12,702)
Pages
Categories
- – Biotech
- – Generics
- – JAMA
- – Medical Devices
- – NEJM
- – Opinion
- – Pharma
- – Policy
- – Reviews, books, devices
- – The Weekly Summary
- Bariatric surgery
- Cardiac surgery
- Cardiology
- Dermatology
- Diabetes and endocrinology
- Emergency medicine
- Gastroenterology and liver
- General surgery
- Genetics
- Geriatrics
- Infectious disease
- Internal Medicine
- Neurology
- Neurosurgery
- Nutrition
- Obstetrics and Gynecology
- Oncology
- Ophthalmology
- Orthopedic surgery
- Pediatrics
- Plastic surgery
- Primary care medicine
- Psychology Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Spine surgery
- Sports medicine
- Transplant surgery
- Trauma Surgery
- Uncategorized
- Urology
- Vascular Surgery
- Z Medical centers
- Baylor
- Boston University
- Cedars Sinai
- Cleveland Clinic
- Columbia
- Cornell
- Duke
- Emory
- George Washington Univ
- Harvard
- Henry Ford
- Iowa State
- Johns Hopkins
- Mayo Clinic
- McMaster University
- Medical University of South Carolina
- Memorial Sloan-Kettering
- Michigan
- National Jewish Health
- NYU
- Ohio State
- Oregon Health and Science University
- UC Davis
- UC San Francisco
- UCLA
- Univ Kentucky
- Univ Maryland
- Univ Miami
- Univ Michigan
- Univ of Louisville
- Univ Texas
- VA Walter Reed
- Vanderbilt
- VCU
- Washington University
- Yale
Category Archives: – Pharma
Once again, daily aspirin is shown to be deadly rather than beneficial
September 16, 2018- by Steven E. Greer, MD The Healthcare Channel has been pounding the table for many years pushing back against the drug
Industry conflicts arise at PCORI threatening any real comparative effectiveness research
February 7, 2014- By Steven E. Greer, MD The Patient Centered Outcome Research Institute (PCORI) was created by the PPACA “ObamaCare” law in 2010.
Posted in - Medical Devices, - Opinion, - Pharma, CMS, Congress, Yale
Leave a comment
Review of immunotherapy and targeted therapy
June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
The Year in Review: 2018
December 29, 2018- by Steven E. Greer, MD The biggest stories this year related
Insurance companies are not paying for Repatha and Praluent
Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.
Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis
January 31, 2017- Interviewed by Steven E. Greer, MD
Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas
Leave a comment
KIT inhibition by Gleevec (imatinib) for severe asthma
May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers
Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology
Leave a comment
Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways
March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Is President Trump on amphetamines? (Yes, he is)
Update January 16, 2018- by Steven E. Greer, MD President Trump’s doctor confirms my diagnosis made in the story below, which was that the slurred
Posted in - Opinion, - Pharma, - Policy, FDA, Internal Medicine, Neurology, Primary care medicine, Rehab
Leave a comment
Bending the cost curve of cancer care
May 25, 2011- Since the approval of Genentech’s costly Avastin in 2004, prominent oncologists have warned that
NBC begins alarming new series to promote the diagnosis of “mental illness” in children
December 11, 2017
Posted in - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Neurology, Neurosurgery, NIH, Pediatrics, Primary care medicine, Psychology Psychiatry, Rehab
Leave a comment
Oh my god, I have a disease!
March 21, 2014- This DTC TV drug ad medicalizing a non-disease really struck us as egregious
Posted in - Pharma, Congress, FDA
Leave a comment
The serious adverse events caused by antipsychotics
February 1, 2014
Posted in - Pharma, FDA
Leave a comment
Steve Bannon and the epidemic of Baby Boomers with mental illness
January 5, 2017- by Steven E. Greer, MD President Trump made news yesterday by issuing a statement firing back at Steve Bannon for allegations
Posted in - Opinion, - Pharma, - Policy, Geriatrics, Neurology, Psychology Psychiatry, Rehab
Leave a comment
The super shady methods of pricing generic drugs in America: case study- Sildenafil
May 15, 2016- by Steven E. Greer, MD The last I read, Teva and Mylan were not supposed to launch their approved generic of Viagra (sildenafil)
Posted in - Generics, - Opinion, - Pharma, CMS, Congress, FDA
Leave a comment
Review of combination immunotherapies seen at ASCO 2016
June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
CDER Director Janet Woodcock on new drug safety strategies
November 16, 2010- by Steven E. Greer, MD We interviewed Dr. Janet Woodcock, long-time Director of CDER, the FDA center responsible
Posted in - Pharma, FDA
Leave a comment
How ADHD became such a prevalent condition
October 7, 2009- interviewed by Steven E. Greer Authors of “ADHD: medicating children”, Rick Mayes and Catherine Bagwell, discuss the history of ADHD
This could be the best interview ever aired on Fox Business
August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same
Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy
Leave a comment
CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?
September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment